GGrantIndex
← Leaderboards

John B Sunwoo

Stanford University

$14,810,025
Attributed
$20,782,502
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.3M · FY200525
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$20,782,502 · 10

By mechanism

U01$6,032,060 · 2
R01$5,748,807 · 3
R35$5,721,403 · 1
U54$1,837,370 · 1
K08$607,986 · 1
R56$435,737 · 1

Top collaborators

Most similar at Stanford University

Same institution · by research overlap

Others in their field

Top investigators on “Tumor

Research focus

TumorMalignant NeoplasmsCellsResponseNeoplastic CellImmuneImmune SystemInsightTissuesMediatingOperative Surgical ProceduresIn VitroFutureCell PhysiologyPrimary NeoplasmAffectImmune ResponseNatural Killer CellsSamplingHead And Neck Squamous Cell CarcinomaReportingIn VivoInvestigationMutation

Grant awards (40)

Reprogramming the Tumor-Immune Interface in Oral Cancer$962,342
R35 · FY2025 · DE · contact PI
Pacific-Stanford PRIMED Program: Training the next generation of clinical oral health researchers$758,372
U01 · FY2025 · DE
Preclinical microphysiological tumor models for nuclear medicine$514,734
R01 · FY2025 · CA
Reprogramming the Tumor-Immune Interface in Oral Cancer$959,255
R35 · FY2024 · DE · contact PI
Pacific-Stanford PRIMED Program: Training the next generation of clinical oral health researchers$741,589
U01 · FY2024 · DE
Preclinical microphysiological tumor models for nuclear medicine$513,249
R01 · FY2024 · CA
Reprogramming the Tumor-Immune Interface in Oral Cancer$994,309
R35 · FY2023 · DE · contact PI
Pacific-Stanford PRIMED Program: Training the next generation of clinical oral health researchers$764,646
U01 · FY2023 · DE
Preclinical microphysiological tumor models for nuclear medicine$529,906
R01 · FY2023 · CA
Reprogramming the Tumor-Immune Interface in Oral Cancer$999,772
R35 · FY2022 · DE · contact PI
Characterizing head and neck tumor neoantigensand T cells: looking beyond the usual suspects$467,405
R01 · FY2022 · DE · contact PI
Reprogramming the Tumor-Immune Interface in Oral Cancer$1,024,729
R35 · FY2021 · DE · contact PI
Characterizing head and neck tumor neoantigensand T cells: looking beyond the usual suspects$470,649
R01 · FY2021 · DE · contact PI
Reprogramming the Tumor-Immune Interface in Oral Cancer$780,996
R35 · FY2020 · DE · contact PI
Characterizing head and neck tumor neoantigensand T cells: looking beyond the usual suspects$492,627
R01 · FY2020 · DE · contact PI
Core 1: Biospecimen and Data Management Core$315,569
U54 · FY2020 · CA · contact PI
Characterizing head and neck tumor neoantigensand T cells: looking beyond the usual suspects$503,244
R01 · FY2019 · DE · contact PI
Core 1: Biospecimen and Data Management Core$401,189
U54 · FY2019 · CA · contact PI
Identification of Cooperative Genetic Alterations in the Pathogenesis of Oral Cancer$924,971
U01 · FY2018 · DE · contact PI
Characterizing head and neck tumor neoantigensand T cells: looking beyond the usual suspects$509,534
R01 · FY2018 · DE
Core 1: Biospecimen and Data Management Core$382,650
U54 · FY2018 · CA · contact PI
Identification of Cooperative Genetic Alterations in the Pathogenesis of Oral Cancer$924,971
U01 · FY2017 · DE · contact PI
Core 1: Biospecimen and Data Management Core$369,028
U54 · FY2017 · CA · contact PI
Identification of Cooperative Genetic Alterations in the Pathogenesis of Oral Cancer$947,802
U01 · FY2016 · DE · contact PI
Core 1: Biospecimen and Data Management Core$368,934
U54 · FY2016 · CA · contact PI
Enhancement of Natural Killer Cell Effector Functions$355,898
R01 · FY2016 · CA · contact PI
Identification of Cooperative Genetic Alterations in the Pathogenesis of Oral Cancer$969,709
U01 · FY2015 · DE · contact PI
Enhancement of Natural Killer Cell Effector Functions$355,898
R01 · FY2015 · CA · contact PI
(PQB2) Identification of Tumor-Derived Activators of Anti-Cancer Immune Responses$180,843
R21 · FY2015 · CA · contact PI
Characterization and Targeting of CD271 in Oral Cancer-Initiating Cells$435,737
R56 · FY2014 · DE · contact PI
Enhancement of Natural Killer Cell Effector Functions$345,221
R01 · FY2014 · CA · contact PI
(PQB2) Identification of Tumor-Derived Activators of Anti-Cancer Immune Responses$218,296
R21 · FY2014 · CA · contact PI
Enhancement of Natural Killer Cell Effector Functions$334,544
R01 · FY2013 · CA · contact PI
Enhancement of Natural Killer Cell Effector Functions$355,898
R01 · FY2012 · CA · contact PI
Mechanisms of Immune Evasion by Head and Neck Cancer$121,597
K08 · FY2008 · DE · contact PI
Mechanisms of Immune Evasion by Head and Neck Cancer$1
K08 · FY2008 · DE · contact PI
Mechanisms of Immune Evasion by Head and Neck Cancer$121,597
K08 · FY2007 · DE · contact PI
Mechanisms of Immune Evasion by Head and Neck Cancer$121,597
K08 · FY2006 · DE · contact PI
Mechanisms of Immune Evasion by Head and Neck Cancer$121,597
K08 · FY2005 · DE
Mechanisms of Immune Evasion by Head and Neck Cancer$121,597
K08 · FY2004 · DE